| abstract |
A b s t r a c t Compounds of general formula (I) wherein R1 represents a) a hydrogen atom or a carboxyl group; b) an alkyl or alkenyl group each having up to 6 carbon atoms and optionally substituted by a phenyl group; c) a mono- or binuclear aryl group optionally substituted by from 1 to 3 substituents selected from alkyl or alkoxy groups each having up to 6 carbon atoms, benzyloxy groups haloalkyl groups having up to 2 carbon atoms, halogen atoms, cyano or nitro groups; amino, carboxyl or hydroxy groups each or the last three groups optionally substituted by methyl and/or ethyl groups, methylenedioxy groups and 0-<3-[4-(2-methoxyphenyl)-1-piperazinyl]-2-hydroxypropyl>-hydroximinomethyl groups; d) a mono- or bicyclic heteroaromatic group having from 1 to 4 nitrogen atoms or a sulphur or oxygen atom in the ring system and being optionally substituted by at most 3 substituents selected from alkyl or alkoxy groups-each having up to 2 carbon atoms,phenylalkyl groups having up to ? carbon atoms in the alkyl moiety, halogen atoms, methylamino and dimethylamino groups; R2 represents a hydrogen atom or an alkyl group having up to 3 carbon atoms, a cycloalkyl group having up to 6 carbon atoms or a phenyl group; or R1 and R2, together with the carbon atom to which they are attached, form a fluorene-9-ylidene group or a cycloaliphatic group having up to 10 carbon atoms optionally containing a hydrocarbon bridging group; R3 represents a hydrogen atom or a hydroxy or acyloxy group; R4 represents a hydrogen atom or an alkyl group having up to 3 carbon atoms or a phenyl group; R5 represents a hydrogen or halogen atom or an alkoxy group having up to 2 carbon atoms or a hydroxy group; and X represents a nitrogen atom or a methine group) and physiologically acceptable acid addition salts thereof, a process for their preparation and a pharmaceutical composition containing said compounds. These compounds find use in the treatment of hypertonic conditions. |